News
VNDA
4.610
+3.13%
0.140
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
NASDAQ · 3d ago
Novavax (NVAX) Q4 Earnings & Sales Miss Estimates, Stock Tanks
NASDAQ · 3d ago
Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down
NASDAQ · 4d ago
Apellis (APLS) Q4 Earnings Miss, Revenues Meet Estimates
NASDAQ · 4d ago
Biotech Stocks Facing FDA Decision In March 2024
NASDAQ · 4d ago
Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates
NASDAQ · 5d ago
Weekly Report: what happened at VNDA last week (0219-0223)?
Weekly Report · 6d ago
Jumpstart Your Portfolio With These 3 Biotech Stocks
Exelixis, Vertex Pharmaceuticals, and Vanda Pharmaceuticals are top biotech stocks. The biotech industry is well-placed to experience significant growth in the foreseeable future. The global biotechnology market is projected to reach $3.88 trillion by 2030. With rapid developments in biotechnology, you could consider investing in biotech stocks to strengthen your portfolio.
Barchart · 6d ago
BIGC, IBRX and VNDA are among after hour movers
Seeking Alpha · 02/23 22:39
Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update
NASDAQ · 02/23 16:12
Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout
NASDAQ · 02/23 16:09
Repligen (RGEN) Stock Down on Q4 Earnings Miss, Revenues Fall Y/Y
NASDAQ · 02/22 15:39
Vanda Pharmaceuticals Sets New Executive Compensation Packages
TipRanks · 02/21 21:44
Weekly Report: what happened at VNDA last week (0212-0216)?
Weekly Report · 02/19 10:35
Vanda Pharma: [Amend]Current report
Press release · 02/17 00:04
Vanda Pharma: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 02/14 12:02
Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash
Seeking Alpha · 02/13 03:59
Earnings Estimates Moving Higher for Vanda (VNDA): Time to Buy?
NASDAQ · 02/12 17:20
Weekly Report: what happened at VNDA last week (0205-0209)?
Weekly Report · 02/12 10:29
More
Webull provides a variety of real-time VNDA stock news. You can receive the latest news about Vanda Pharma through multiple platforms. This information may help you make smarter investment decisions.
About VNDA
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).